AAX Biotech aims to enhance growth with two new appointments
Ella Day | April 10, 2025 | Appointment | Business Development, Recruitment, Research and Development | AAX Biotech, Immunology, Oncology, R&D development, antibody therapeutics, business development
AAX Biotech has appointed Ionut Gabriel Dumitru (pictured left) as senior scientist and Kushal Sejwal (pictured right) as business developer, contributing to its strategy to develop its research and business.
The company experiences growing interest in its Seqitope and Opti-mAb technologies, platforms pioneering its mission to develop innovative antibody therapeutics. Both support the development of more effective drug candidates by enhancing epitope resolution, antibody stability and manufacturability.
Commenting on growing interest in the platforms, Maria Lisa Knudsen, chief executive officer, said: “Strengthening both our research and development (R&D) and commercial teams is a natural next step, and I’m very pleased to welcome Ionut and Kushal to AAX Biotech.”
As senior scientist, Dumitru will lead all R&D initiatives, advancing the company’s platform’s epitope mapping capabilities. He brings a wealth of experience in next-generation sequencing, bioinformatics and antibody engineering.
Sejwal will focus on AAX’s strategic partnerships and business growth. He has over a decade of experience within the intersection of science and strategy, specifically commercialisation efforts in structural biology and cryo-electron microscopy.
Dumitru commented: “I am excited to join AAX and contribute to advancing its innovative technologies, integrating protein biology with cutting-edge robotics and machine learning.”
Sejwal also stated: “I am looking forward to contributing to AAX Biotech’s growth by building strong collaborations and expanding the reach of Seqitope and Opti-mAb in the rapidly evolving field of antibody therapeutics.”
Ella Day
10/4/25
Related Content
AAX Biotech and ToxoTech partner to develop next-gen biotherapeutics for neurological disorders
AAX Biotech, a biotech company specialising in next-generation antibody therapeutics, has entered a strategic partnership …
AAX Biotech and Daiichi Sankyo partner to evaluate antibody therapeutics
AAX Biotech, a Swedish biotechnology company specialising in next-generation antibody therapeutics, has launched a strategic …
AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …
